Analyst Caitlin Roberts of Canaccord Genuity maintained a Buy rating on Establishment Labs Holdings, with a price target of $72.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Caitlin Roberts’s rating is based on the promising growth prospects of Establishment Labs Holdings, particularly in the US market. The company has demonstrated strong pivotal trial data and received PMA approval, which positions it well against competitors who are not prioritizing their breast segments. This strategic advantage, coupled with innovative developments in minimally invasive surgery, supports the expectation that ESTA will continue to capture market share.
Caitlin Roberts also highlights the company’s financial outlook, noting its ability to achieve profitability gains and improve margins due to the premium pricing of its products in the US. The planned expansion of its sales force is expected to support this growth without proportionally increasing commercial investments, thereby enhancing EBITDA and cash flow. With a robust pipeline and favorable competitive environment, ESTA is poised for sustained top-line momentum, reinforcing the Buy rating.
In another report released on December 10, Needham also reiterated a Buy rating on the stock with a $84.00 price target.